MarketPulse

barzolvolimab

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Celldex

Celldex's Barzolvolimab Shows Durable Efficacy in Retreatment Trial

Celldex presented Phase 2 data showing barzolvolimab retreatment achieves 62% and 60% complete response rates in cold urticaria and symptomatic dermographism patients.
CLDXbarzolvolimabcold urticaria
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Celldex Touts Sustained Efficacy Data for Mast Cell Antibody Barzolvolimab

Celldex's mast cell antibody barzolvolimab showed strong Phase 2 efficacy for urticaria, with 71% of patients achieving complete response. Phase 3 data expected Q4 2026.
CLDXbarzolvolimabchronic spontaneous urticaria